Ligandrol LGD-4033
LGD 4033, also known as Ligandrol, VK5211 or Anabolicum, is a Selective Androgen Receptor Modulator (SARM). Several animal studies have shown that it increases anabolic activity in muscles. It has also shown positive effects on bone density in male rats with hypogonadism and has achieved success in treating female postmenopausal rats suffering from osteoporosis.
LGD 4033: Effects on Bones and Muscles
Research presented at the 62nd Annual Meeting of the Gerontology Society of America has shown that use of LGD 4033 in animals after 12 weeks increases both fracture resistance and bone mineral density. These effects were evident in cancellous bone at a dose of 0.3 mg/kg per day and in cortical bone at a dose of 0.03 mg/kg per day (source).
LGD 4033 increased skeletal muscle mass and muscle fiber diameter in both hypogonadal and normal rats. This correlated with increased contractile force of the muscles, suggesting improved muscle strength.
In an exciting study conducted by Roche et al., 3-month-old Sprague-Dawley rats were ovariectomized and treated with LGD 4033 for 5 weeks. The rats in the experimental groups received doses ranging from 0.04 to 4 mg/kg body weight per day. Subsequently, analyzes were performed on fiber size, capillary density and various enzyme levels. In addition, weights of the uterus, gastrocnemius, and soleus muscles were measured before and after treatment (source).
When analyzing the effects of LGD 4033, the researchers also took samples from the quadriceps femoris muscle to measure changes in intramuscular fat levels. Treatment with LGD 4033 resulted in increased capillary density and higher enzyme activity of both citrate synthase in the gastrocnemius muscle and lactate dehydrogenase in the longissimus muscle (source).
CONCENTRATION
10 mg / ml.
DISCLAIMER
This material is sold for use in laboratory research only. Terms of sale apply. Not for human consumption, nor for medical, veterinary or household use. Familiarize yourself with our DISCLAIMER before ordering.
Data sheet
LGD4033 - Oplossing, 300 mg (10 mg / ml)
|
Application |
Selective Androgen Receptor Modulator |
|
CAS |
1165910-22-4 |
|
molar massa |
338.25g/mol |
|
Chemical formula |
C14H12F6N2O |
|
IUPAC name |
4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile |
|
Synonyms |
LG4, LG-4, 1165910-22-4, UNII-1EJT54415A, 4-((R)-2-((R)-2,2,2-Trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2 -(trifluoromethyl)benzonitrile, 1EJT54415A, 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]-1-pyrrolidinyl]-2-(trifluoromethyl)benzonitrile, 4-{ (2R)-2-[(1R)-2,2,2-Trifluoro-1-hydroxyethyl]-1-pyrrolidinyl}-2-(trifluoromethyl)benzonitrile, SCHEMBL221159, DTXSID10657620, EX-A729, PUBCHEM_44137686, BCP07128, s8822, ZINC95830588, AKOS022173564, CS-4667, DB13934, AC-30218, AK141891, HY-13981, AX8259791, A14346, J-690039, Q21098841, 4-[(2R)-2-[(1R)-2,2,2- TRIFLUORO-1-HYDROXYETHYL]PYRROLIDIN-1-YL]-2-(TRIFLUOROMETHYL)BENZONITRILE, Benzonitrile, 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]-1 -pyrrolidinyl]-2-(trifluoromethyl)- |
|
Bulletin |
room temperature |
|
Solubility |
Soluble in ethanol, PEG400, PPG, glycerin |
|
Organoleptic profile |
Lightly sealed clear liquid |
|
Physical form |
molding solution in PPG |
|
Specification |
10mg/mL ±5% |
|
Terms and conditions |
This material is sold for use in laboratory research only. Terms of sale apply. Not for human consumption, nor for medical, veterinary or household use. Please familiarize yourself with our terms and conditions & disclaimer before ordering. |
Choose options